The two companies have signed a letter of intent to come to a collaboration agreement and both companies have expressed confidence in forming a mutually beneficial alliance.
Konstantinos Kardiasmenos, CEO of NextGen, said: “SymbioTec’s drug Oncohist is capable of destroying cancer cells. The drug uses an approach fundamentally different from all currently used methods and represents a real potential to replace existing cancer therapies.”